167 related articles for article (PubMed ID: 20824399)
1. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation.
Ishida Y; Terasako K; Oshima K; Sakamoto K; Ashizawa M; Sato M; Kikuchi M; Kimura S; Nakasone H; Okuda S; Kako S; Yamazaki R; Nishida J; Kanda Y
Int J Hematol; 2010 Oct; 92(3):542-6. PubMed ID: 20824399
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
3. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M
Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Teng CL; Yu JT; Chen HC; Hwang WL
Ann Hematol; 2013 Aug; 92(8):1137-9. PubMed ID: 23307602
[No Abstract] [Full Text] [Related]
6. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
10. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Gruber F; Mustjoki S; Porkka K
Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
[TBL] [Abstract][Full Text] [Related]
11. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
Doki N; Ohashi K; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H
Pathol Oncol Res; 2014 Jan; 20(1):61-6. PubMed ID: 23821455
[TBL] [Abstract][Full Text] [Related]
13. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
[TBL] [Abstract][Full Text] [Related]
14. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant.
Fava C; Rege-Cambrin G; Busca A; Gottardi E; Daraio F; Saglio G
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S272-5. PubMed ID: 24290212
[No Abstract] [Full Text] [Related]
15. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G
Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733
[No Abstract] [Full Text] [Related]
16. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia].
Li Y; Wang BJ; Liu W; Liang ZY; Yin Y; Dong YJ; Wang Q; Sun YH; Xu WL; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):18-23. PubMed ID: 32027247
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse.
Kang BW; Moon JH; Chae YS; Kim JG; Kim SN; Sohn SK
Acta Haematol; 2010; 123(4):242-7. PubMed ID: 20460883
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
Cai W; Liu B; Xu Y; Chen S; Sun A; He J; Shen H; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):105-9. PubMed ID: 27014978
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy comparison of sequential treatment with first-line administration of second-generation and first-generation tyrosine kinase inhibitors in patients with Ph
Yang F; Cai WZ; Yang XD; Chen SN; Tang XW; Sun AN; Wu DP; Qian WQ; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):110-115. PubMed ID: 29562444
[No Abstract] [Full Text] [Related]
[Next] [New Search]
